ArticleCase reports in gastrointestinal medicine2025
Rare Case of Duodenal Metastasis From Colon Cancer: Review of Literature and Insights on Novel Therapies.
Article in Case reports in gastrointestinal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Duodenal and cutaneous metastases from advanced rectal cancer: a rare case report.Frontiers in oncology · 2026Article
- Emerging KRAS G12D inhibitor in the treatment of digestive system tumors: opportunities and challenges.Translational gastroenterology and hepatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastasis to the duodenum from colorectal cancer is exceptionally rare and presents significant diagnostic and therapeutic challenges. We describe a 68-year-old female with right colon adenocarcinoma, who developed a duodenal metastasis despite treatment with FOLFOX chemotherapy. Transition to FOLFIRI yielded limited success, emphasizing the need for innovative approaches. Genetic analysis revealed a KRAS G12D mutation, for which targeted therapies are not yet approved. Immunohistochemistry confirmed the gastrointestinal origin of the duodenal mass. Literature indicates that surgical resection can offer curative potential in select cases, although it was not viable here. Emerging KRAS-targeted agents, such as MRTX1133, represent promising options for addressing this mutation. This case underscores the challenges of managing rare metastatic patterns, the potential of personalized therapies, and the necessity for further research into innovative treatments for advanced colorectal cancer. It highlights the importance of developing targeted strategies to improve outcomes for patients with such complex metastatic diseases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.